# BLINCYTO® (blinatumomab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/blinatumomab

> The FDA approved BLINCYTO® (blinatumomab), sponsored by AMGEN INC (AMGN), on Jun 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | BLINCYTO® (blinatumomab) |
| Codes |  |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | B Precursor Acute Lymphoblastic Leukemia, [Systemic Lupus Erythematosus](https://sec-api.dev/indications/systemic-lupus-erythematosus) |
| Modality | antibody |
| FDA designations | breakthrough, priority review |

## Timeline

### March 11, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125557 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority PRIORITY; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22
- openFDA Drugs@FDA: "BLA125557 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority PRIORITY; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22

### June 20, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125557 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20230620, review_priority UNKNOWN; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22
- openFDA Drugs@FDA: "BLA125557 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230620, review_priority PRIORITY; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22

### Jun 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0000318154-25-000010): "In June 2024, we announced BLINCYTO received approval from the FDA in frontline consolidation for patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL)." https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm

### June 14, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125557 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20240614, review_priority PRIORITY; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-08-05, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0000318154-25-000054): "The Company is planning to initiate a potentially registration-enabling Phase 2 portion of this study in both adults and adolescents in H2 2025." https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm

### January 6, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06054113 (Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-06 (ACTUAL); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06054113

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06570798 (A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-06 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06570798

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06570798 (A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-06 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06570798

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04994717 (Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04994717

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04994717 (Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04994717

## Same indication

- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs) (AZN)
- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [MEDI-546](https://sec-api.dev/pdufa/medi-546) (AZN)
- [MK-6194](https://sec-api.dev/pdufa/mk-6194) (MRK)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv) (SNY)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

Calendar months: [August 2028](https://sec-api.dev/fda-calendar/2028-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/blinatumomab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BLINCYTO® (blinatumomab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/blinatumomab

```bibtex
@misc{secapidev_pdufa_blinatumomab_20261116,
  title        = {BLINCYTO® (blinatumomab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/blinatumomab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_blinatumomab_20261116","title":"BLINCYTO® (blinatumomab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/blinatumomab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
